Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 in previously treated metastatic melanoma
NCT00093119Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2003
- Primary completion
- Feb 2005
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in melanoma, sponsored by Celgene Corporation. Primary endpoint: Anti-tumor activity. Started Jul 2003; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00093119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093119.